ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,452Medicare Part D Prescriptions Filled, Including Refills

Rank: 76 out of 337

$492K Total Retail Price of All Prescriptions

Rank: 79 out of 337

377 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
26% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 377 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

7% of this provider’s 377 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 8,278 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$52 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
SIMVASTATIN 476 426 1 1
LISINOPRIL 389 328 2 2
PRAVASTATIN SODIUM 294 278 3 14
AMLODIPINE BESYLATE 283 278 4 3
OMEPRAZOLE 278 241 5 4
LEVOTHYROXINE SODIUM 261 250 6 5
FUROSEMIDE 234 234 7 8
HYDROCODONE-ACETAMINOPHEN 217 190 S3 8 13
LOSARTAN POTASSIUM 176 165 9 15
ATORVASTATIN CALCIUM 175 157 10 7
ATENOLOL 162 162 11 10
LOVASTATIN 155 144 12 24
HYDROCHLOROTHIAZIDE 145 136 13 9
METOPROLOL TARTRATE 135 133 14 6
TRAZODONE HCL 132 113 15 16
TAMSULOSIN HCL 128 98 16 25
ZOLPIDEM TARTRATE 126 98 17 23
QUINAPRIL HCL 119 119 18 50
VERAPAMIL ER 116 92 19 77
CITALOPRAM HBR 116 102 19 17
METOPROLOL SUCCINATE 107 91 21 21
GLIMEPIRIDE 106 91 22 55
METFORMIN HCL ER 104 95 23 52
NEXIUM 102 96 24 56
DIGOXIN 96 96 25 58
OXYCODONE HCL 95 22 S2 26 63
METFORMIN HCL 90 71 27 12
IBUPROFEN 81 53 28 64
FLUOXETINE HCL 79 47 29 57
MELOXICAM 76 66 30 54
MIRTAZAPINE 73 73 31 27
GABAPENTIN 71 67 32 20
CLOPIDOGREL 70 70 33 42
WARFARIN SODIUM 68 65 34 11
TRAMADOL HCL 65 64 35 32
POLYETHYLENE GLYCOL 3350 64 45 36 47
DONEPEZIL HCL 63 63 37 22
JANUVIA 63 40 37 81
TRIAMTERENE-HCTZ 61 49 39 39
DILTIAZEM 24HR ER 60 60 40 76
ZETIA 55 55 41 89
SPIRIVA 54 49 42 43
DIOVAN 54 54 42 26
BENICAR 53 53 44 110
PROPRANOLOL HCL 53 53 44 121
BENAZEPRIL HCL 51 51 46 109
ALLOPURINOL 50 50 47 28
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 21, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.